Vitrolife completes acquisition of Cryo Management Ltd

On June 29 Vitrolife announced that the company had entered into an agreement to
acquire 100% ownership in Cryo Management Ltd. Vitrolife has now completed the
transaction and Cryo Management Ltd is now a part of Vitrolife.
Cryo Management Ltd is one of the world’s leading players within time-lapse for
IVF, developer of Primo Vision time-lapse embryo monitoring system. The company
has approximately 20 employees and is based in Hungary. The acquisition was
completed under essentially the same conditions as were communicated on June 29.

“We are pleased to be able to welcome our new colleagues within Cryo to the
Vitrolife Group. There continues to be great and increasing interest in the
market for the company’s product for the monitoring of embryos, Primo Vision,
and we look forward to being able to offer this world-leading product to current
and new customers,” says Thomas Axelsson, CEO.

October 4, 2012

VITROLIFE AB (publ)

Thomas Axelsson, CEO
Queries should be addressed to:

Thomas Axelsson, CEO, phone 46 31 721 80 01

Mikael Engblom, CFO, phone 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
October 4, 2012 at 4:30 p.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
Vitrolife (http://www.vitrolife.com/en/Corporate/) is a global
biotechnology/medical device Group. The
Fertility (http://www.vitrolife.com/en/Fertility/) product area works with
nutrient solutions (media), cryopreservation products and advanced consumable
instruments such as needles and pipettes, for the treatment of human
infertility. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes.

Vitrolife (http://www.vitrolife.com/en/Corporate/) today has approximately 220
employees and its products are sold in almost 90 markets. The company is
headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife
share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on
NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/